<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02806895</url>
  </required_header>
  <id_info>
    <org_study_id>15-004</org_study_id>
    <secondary_id>2015-003930-28</secondary_id>
    <nct_id>NCT02806895</nct_id>
  </id_info>
  <brief_title>Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in OSA</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Crossover On-Road Driving Study Assessing the Effect of JZP-110 on Driving Performance in Subjects With Excessive Sleepiness Due to Obstructive Sleep Apnea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jazz Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jazz Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a randomized, double-blind, placebo-controlled, crossover study to evaluate the
      effect of JZP-110 on driving performance in subjects with excessive sleepiness due to
      obstructive sleep apnea.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Standard deviation of lateral position (SDLP)</measure>
    <time_frame>At 2 hours post-dose (approximately at Tmax)</time_frame>
    <description>Subject will be instructed to drive with steady lateral position between the delineated boundaries of the slower (right) traffic lane, while maintaining a constant speed of 95 km/hr. Deviation is measured by the vehicle's speed and lateral distance to the left lane line and will be continuously recorded.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Standard deviation of lateral position (SDLP)</measure>
    <time_frame>At 6 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with improved or impaired driving on JZP-110 compared to placebo</measure>
    <time_frame>At Days 7 and 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standard Deviation of Speed (SDS)</measure>
    <time_frame>At Days 7 and 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychomotor Vigilance Test (PVT) number of lapses</measure>
    <time_frame>At Days 7 and 14</time_frame>
    <description>Reaction Time (RT) in milliseconds &gt; 500 milliseconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychomotor Vigilance Test (PVT) mean reaction time</measure>
    <time_frame>At Days 7 and 14</time_frame>
    <description>In milliseconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychomotor Vigilance Test (PVT) inverse reaction time</measure>
    <time_frame>At Days 7 and 14</time_frame>
    <description>Expressed as 1/reaction time in milliseconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychomotor Vigilance Test (PVT) number of errors of commission</measure>
    <time_frame>At Days 7 and 14</time_frame>
    <description>Number of responses without a stimulus or response time &lt; 100 milliseconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toronto Hospital Alert Test (THAT)</measure>
    <time_frame>At Days 7 and 14</time_frame>
    <description>10-item self-report questionnaire designed to measure perceived alertness</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <condition>Excessive Sleepiness</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Once daily dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JZP-110</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>150 mg/day for first 3 days and 300 mg/day for next 4 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JZP-110</intervention_name>
    <arm_group_label>JZP-110</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, age 21 to 65 years inclusive

          2. Diagnosis of obstructive sleep apnea (OSA) per ICSD-3

          3. BMI 18 to &lt;40 kg/m2

          4. Willing and able to provide written informed consent

        Exclusion Criteria:

          1. Female subjects who are pregnant, nursing, or lactating

          2. Any other clinically relevant medical, behavioral, or psychiatric disorder other than
             OSA that is associated with excessive sleepiness

          3. History or presence of bipolar disorder, bipolar related disorders, schizophrenia,
             schizophrenia spectrum disorders, or other psychotic disorders according to DSM-5
             criteria

          4. History or presence of any unstable medical condition, behavioral or psychiatric
             disorder (including active suicidal ideation), or surgical history that could affect
             the safety of the subject or interfere with study efficacy and/or safety assessments
             per the judgment of the investigator

          5. History of bariatric surgery within the past year or a history of any gastric bypass
             procedure

          6. Presence or history of significant cardiovascular disease

          7. Unable to washout or refrain from taking any over-the-counter (OTC) or prescription
             medications that could affect sleep-wake function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan Chen, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Jazz Pharmaceuticals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tatiana Kharkevitch, MD</last_name>
    <role>Study Director</role>
    <affiliation>Jazz Pharmaceuticals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan Ramaekers, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastricht University</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6229</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annamiek Vermeeren, MD</last_name>
      <phone>+31 (0)43 3881952</phone>
      <email>a.vermeeren@maastrichtuniversity.nl</email>
    </contact>
    <investigator>
      <last_name>Jan Ramaekers, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2016</study_first_submitted>
  <study_first_submitted_qc>June 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2016</study_first_posted>
  <last_update_submitted>March 12, 2018</last_update_submitted>
  <last_update_submitted_qc>March 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Driving</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Disorders of Excessive Somnolence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

